Veru Inc. is an oncology and urology biopharmaceutical company developing and commercializing novel medicines for the prostate cancer continuum of care and urology specialty pharmaceuticals.
December 12, 2019, 8am ET
Join us to learn the recent news and updates in Veru’s Q4 and Year End Earnings Call.
Listen to other presentations and conference calls
We’re looking forward to updating you on the Q4 activities and year end earnings at Veru. As soon as the conference starts, the link will be available. See you there!
October 2, 2019
Watch the replay of the webcast of our presentation at the 2019 Cantor Fitzgerald Global Healthcare Conference.
(View Slide Deck)
December 5, 2019
Veru to Report Fiscal 2019 Fourth-Quarter, Full-Year Financial Results, Host Conference Call on December 12th
Veru Announces Full Enrollment of Phase 2 Trial in Men with Prostate Cancer Treatment Induced Hot Flashes